Prevalence of congenital defects of heart and large vessels in adults

 I.G. Lebid

References

  1. Boguta L.Yu., Rudenko N.N., Emets І.N. Surgical Treatment Of Congenital Heart Diseases In Infants. Sovremennaya Pediatriya [Sovremennaya Pediatriya] 2013;7:145-147 (in Ukr.).
  2. Boсkeria L.A., Stupakov I.N., Gudkova R.G., Ivanovа E.Yu. Congenital anomalies (defects) of the circulatory system among the population of russia and their surgical treatment (2005–2014). Thoracic and Cardiovascular Surgery, 2016; 58 (4): 202-206 (in Russian)
  3. Volosovets O.P. State Of Assisting Children With Cardiorheumatological Pathology. Zdorove rebenka 2015;5:125-135. (in Ukr.).
  4. Gandzyuk V.A. Dynamics Of Morbidity And Prevalence Of Cardiovascular Diseases Among Ukrainian Population At The Present Stage: National And Regional Aspects. Visnyk sotsial'noi hihiieny ta orhanizatsii okhorony zdorov'ia Ukrainy 2014;2:74-78. (in Ukr.).
  5. Yemets І.N., Rudenko N.N., Vorobeva G.M Transposition of Grate Arteries (clinic, diagnostic, treatment) Ternopil' TDMU.«Ukrmedknyha.2012.221p. (in Ukr.)
  6. Kirillov K.O., Nachinkin V.V., Kim A.I., Yurlov I.A. Epidemiology Of Congenital Heart Disease And Ways Of Optimization Of Cardiac Surgical Care In The Volgograd Region Children's Heart and Vascular Diseases [Detskie Bolezni Serdtsa i Sosudov] 2014;2:30-33. (in Russ.)
  7. Clinical guidelines for the management of adults with congenital heart disease Moscow: Yzd-vo NTsSSKh ym. A.N. Bakuleva RAMN 2010.358p. (in Russ.)
  8. Kovalenko V.M., Dorogoi A.P. Cardiovascular disease: medical and social value and strategy of cardiology in Ukraine. Ukrainian cardiology journal [Ukrains'kyj kardiolohichnyj zhurnal] 2016;4 (suppl.3):5-14. (in Ukr.)
  9. Lazoryshinets V.V. Tactical and strategic issues of Ukrainian cardiac surgery and interventional cardiology as effective tools to ensure the current level of aid to the population with cardiovascular disease Cardiovascular Surgery Herald [Visnyk sertsevo-sudynnoi khirurhii]2016;3(suppl.26):9-10 (in Ukr.)
  10. Moroz D.M., Manojlenko T.S., Dorohoj A.P., Handziuk V.A., Revenko I.L. Problems of health and medical care and model improvements in current conditions: manual / pid red. Kovalenka V.M., Kornats'koho V.M. National Scientific Center "M.D. Strazhesko Institute Of Cardiology”, Kyiv 2016.259p. (in Ukr.)
  11. The population of Ukraine for 2015. Demographic Yearbook / response. MB Timonina; State Statistics Service of Ukraine. Kyiv. 2016.119p. (in Ukr.)
  12. Siromaha S.О., Rudenko К.V., Zalevskyi V.P., Truba Ya.P., Prokopovych L. М., Fylypchuk V.V., Lazoryshynez V.V., Knyshov G.V Treatment Experience Of Critical Congenital Heart Diseases And Critical Conditions Caused By Them As Element Of Urgent Or Emergency Cardiosurgery Cardiovascular Surgery Herald [Visnyk sertsevo-sudynnoi khirurhii]2014;22:320-325. (in Ukr.)
  13. Baumgartner H., Bonhoeffer P., De Groot N.M. de Haan, F., Deanfield, J. E., Galie, N., Meijboom, F. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). European heart journal. 2010;ehq 249.
  14. Bhardwaj R., Rai S.K., Yadav A.K. Lakhotia S., Agrawal D., Kumar A., Mohapatra B. Epidemiology of congenital heart disease in India. Congenital heart disease 2015;10(5):437-446.
  15. Bhatt A.B., Foster E., Kuehl K. Alpert J., Brabeck S., Crumb S., Mital S. Congenital Heart Disease in the Older Adult A Scientific Statement From the American Heart Association. Circulation. 2015;131(21):1884-1931.
  16. Billett J. Cowie M.R., Gatzoulis M.A. Muhll I. V., Majeed A. Comorbidity, healthcare utilisation and process of care measures in patients with congenital heart disease in the UK: cross-sectional, population-based study with case–control analysis. Heart 2008;94(9):1194-1199.
  17. Costello J.M., Mussatto K., Cassedy A. Wray J., Mahony L., Teele S.A., Marino, B.S. Prediction by clinicians of quality of life for children and adolescents with cardiac disease. J. Pediatr. 2015;66(3):679-683.
  18. Daliento L. Cecchetto A., Bagato F., Dal Bianco, L.  A new view on congenital heart disease: clinical burden prevision of changing patients. Journal of Cardiovascular Medicine. 2011;12 (7):487-492.
  19. Engelfriet P., Boersma, E., Oechslin, E.,et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period // European heart journal. – 2005. – Vol.26 (21). – С. 2325-2333
  20. Fredriksen P. M., Roislien J., Thaulow E. The estimated number of patients with adult congenital heart defects in Norway. Scandinavian journal of medicine & science in sports. 2008;18(4):520-525.
  21. Gilboa S.M. Devine O.J., Kucik J.E. Gilboa S. M., Devine O.J., Kucik J.E., Oster, M.E., Riehle-Colarusso T., Nembhard W.N., Marelli A.J. Congenital heart defects in the United States: estimating the magnitude of the affected population in 2010. Circulation 2016;P. CIRCULATIONAHA. 115.019307.
  22. Goodman RA, Posner SF, Huang ES, Parekh AK, Koh HK. Defining and measuring chronic conditions: imperatives for research, policy, program, and practice. Preventing chronic disease 2013;10:234-45.
  23. Hoffman J.I., Kaplan S., Liberthson R.R. Prevalence of congenital heart disease. Am Heart J. 2004;147:425-439.
  24. Liu X.K., Sang H., Xiu J.F. Li X, Li J, Hu DY. The prevalence of congenital heart disease in students of Liangshan prefecture in Sichuan province. Zhonghua nei ke za zhi 2013;52(6):494-497.
  25. Marelli A.J. Mackie A.S., Ionescu-Ittu R., Rahme E, Pilote L.. Congenital heart disease in the general population changing prevalence and age distribution. Circulation. 2007;115(2):163-172.
  26. Marelli A.J., Ionescu-Ittu R., Mackie A., Guo L., Dendukuri N., Kaouache M. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation. 2014;130(9):749-756.
  27. Mnozanffarian D. Benjamin E.J., Go A.S. Arnett DKBlaha MJCushman Mde Ferranti SDesprés JPFullerton HJHoward VJHuffman MDJudd SEKissela BMLackland DTLichtman JHLisabeth LDLiu SMackey RHMatchar DBMcGuire DKMohler ER 3rdMoy CSMuntner PMussolino MENasir KNeumar RWNichol GPalaniappan LPandey DKReeves MJRodriguez CJ, Sorlie PDStein JTowfighi ATuran TNVirani SSWilley JZWoo DYeh RW, Turner MBAmerican Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation 2015;131:e29-322.
  28. Robbers-Visser D., Mulder B.J.M. The Netherlands as frontrunner of collaborative research in adult congenital heart disease. Netherlands Heart Journal 2016;24(11):625-627.
  29. Shiina Y., Toyoda T., Kawasoe Y. Tateno SShirai TWakisaka YMatsuo KMizuno YTerai MHamada HNiwa K. Prevalence of adult patients with congenital heart disease in Japan. International journal of cardiology. 2011;146(1):13-16.
  30. Somerville J. Grown-up congenital heart (GUCH) disease: current needs and provisions of service for adolescents and adults with congenital heart disease in the UK. Heart.2002;88(Suppl I):i1-i14.
  31. van der Bom T. Mulder B.J., Meijboom F.J. van Dijk APPieper PGVliegen HWKonings TCZwinderman AHBouma BJ. Contemporary survival of adults with congenital heart disease. Heart 2015;P. heartjnl-2015-308144.
  32. van der Bom T. et al. The prevalence of adult congenital heart disease, results from a systematic review and evidence based calculation. American heart journal 2012;164(4):568-575.
  33. van der Linde D., Konings E.E., Slager M.A.  Witsenburg MHelbing WA, Takkenberg JJRoos-Hesselink JW. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58:2241–2247.
  34. Videbaek J, Olsen M, Laursen HB Prevalence of Grown Up Congenital Heart Disease (GUCH) patients in the Danish population: a nationwide population-based study. Eur Heart J. 2009;30(Suppl 1):802 Abstract.
  35. Warnes CA, Liberthson R, Danielson GK, Dore AHarris LHoffman JI, Somerville JWilliams RGWebb GD.. Task force 1: the changing profile of congenital heart disease in adult life. J. Am. Coll. Cardiol. 2001;37:1170-1175.
  36. Warnes C.A., Williams R.G., Bashore T.M Child JSConnolly HMDearani JAdel Nido PFasules JWGraham TP JrHijazi ZMHunt SAKing MELandzberg MJMiner PDRadford MJWalsh EPWebb GDSmith SC JrJacobs AKAdams CDAnderson JLAntman EMBuller CECreager MA, Ettinger SMHalperin JLHunt SAKrumholz HMKushner FGLytle BW, Nishimura RAPage RLRiegel BTarkington LGYancy CWAmerican College of CardiologyAmerican Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease)American Society of EchocardiographyHeart Rhythm Society; International Society for Adult Congenital Heart DiseaseSociety for Cardiovascular Angiography and InterventionsSociety of Thoracic Surgeons. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Journal of the American College of Cardiology. 2008;52(23):e143-e263.
  37. Webb G. Mulder B.J., Aboulhosn J. Daniels CJElizari MAHong GHorlick E, Landzberg MJMarelli AJO'Donnell CPOechslin ENPearson DDPieper EP, Saxena ASchwerzmann MStout KKWarnes CAKhairy P. The care of adults with congenital heart disease across the globe: Current assessment and future perspective: A position statement from the International Society for Adult Congenital Heart Disease (ISACHD). International journal of cardiology. 2015;195:326-333.

 

 

[PDF] [Contents]  

  

 

Aortic allografts in treatment of aortic valve and ascending aorta prosthetic endocarditis

S.V. Spiridonov

References

  1. Anguera I, Miro JM, Cabell CH, et al. ICEMD Investigators. Clinical characteristics and outcome of aortic endocarditis with periannular abscess in the International Collaboration on Endocarditis Merged Database. Am. J. Cardiol. 2005;96:976–981.
  2. Anguera I, Miro JM, Vilacosta I, et al. Aortocavitary fistula in infective endocarditis Working Group. Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality. Eur. Heart J. 2005;26:288–297.
  3. Crawford ES, Crawford JL, Safi HJ, Coselli JS. Redo operations for recurrent aneurysmal disease of the ascending aorta and transverse aortic arch. Ann. Thorac. Surg. 1985;40:439–455.
  4. Dossche KM, Defauw J.J, Renst SM. Allograft aortic root replacement in prosthetic aortic valve endocarditis: a review of 32 patients. Ann. Thorac. Surg. 1997;63:1644–1649.
  5. Garrido-Olivares L, Maganti M, Armstrong S, et al. Clinical outcomes of aortic root replacement after previous aortic root replacement. J. Thorac. Cardiovasc. Surgery. 2013;146,3:611–615. doi.org/10.1016/j.jtcvs.2012.07.041
  6. Hoen B, Alla F, Selton-Suty Ch, et al. Changing profile of infective endocarditis (Result of a 1-year survey in France). JAMA. 2002;288:75–81.
  7. Kirsch M, Radu NC, Mekontso-Dessap A, et al. Aortic root replacement after previous surgical intervention on the aortic valve, aortic root, or ascending aorta. J. Thorac. Cardiovasc. Surg. 2006. 131:601–608.
  8. Krasopoulos G, David TE, Armstrong S. Custom-tailored valved conduit for complex aortic root disease. J. Thorac. Cardiovasc. Surg. 2008;135:3–7.
  9. Leyh RG, Knobloch K, Hagl C, et al. Replacement of the aortic root for acute prosthetic valve endocarditis: prosthetic composite versus aortic allograft root replacement. J. Thorac. Cardiovasc. Surg. 2004;127:1416–20.
  10. Luciani N, De Geest R, Anselmi A, et al. Results of Reoperation on the Aortic Root and the Ascending Aorta. Ann. Thorac. Surg. 2006;92:898–903.
  11. Moreillon P, Que Y.A. Infective endocarditis. Lancet. 2004;363:139–149.
  12. Musci M, Weng Y, Hubler M, et al. Homograft aortic root replacement in native or prosthetic active infective endocarditis: twenty-year single-center experience. J. Thorac. Cardiovasc. Surg. 2010;139:665–673.
  13.  Navia JL. Aortic root replacement with cryopreserved homograft for aortic valve endocarditis.– 2nd Virtual Congress of Cardiology: Int. Congr. of Cardiology on Internet, 1 Sept.– 30 Nov. 2001 / Argentine Federation of Cardiology.– 2001.– Date of access: 10.11.2014. URL: www.fac.org.ar?/scvc/llave/navia1i.htm.
  14. Netzer ROM, Altwegg SC, Zollinger E, et al. Infective endocarditis: determinants of long term outcome. Heart. 2002;88:61–66.
  15. Petrou M, Wong K, Albertucci M. Evaluation of unstented aortic homograft for the treatment of prosthetic aortic valve endocarditis. Circulation. 1994;90:II98–II204.
  16. Raanani E, David TE, Dellgren G, et al. Redo aortic root replacement: experience with 31 patients. Ann. Thorac. Surg. 2001;71:1460–1463.
  17. Tuna IC, Orszulak AT, Schaff HV. Results of homograft aortic valve replacement for active endocarditis. Ann. Thorac. Surg. 1990;49:619–62.
  18. Vogt PR, et al. Сryopreserved arterial homografts for in situ reconstruction of mycotic aneurysms and prosthetic graft infection. Eur. J. Cardiothorac. Surg. 1995;9,9:502–506
  19. Yankah AC, et al. Surgical management of acute aortic root endocarditis with viable homograft: 13-year experience. Eur. J. Cardiothorac. Surg.  2002;21,2:260–267. 

.

 

[PDF] [Contents]  

  

 

The evaluation of the predictors of left ventricular systolic function improvement in patients with severe aortic stenosis after aortic valve replacement

N.V. Ponych, O.J. Zharinov, O.A. Yepanchintseva, B.M. Todurov

References

  1. Baumgartner H, Hung J, Bermejo J. EAE/ASE recommendations of echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. Eur. J. Echocardiography. 2009;10:1–25.
  2. Ben-Dor І, et al. Comparison of outcome of higher versus lower transvalvular gradients in patients with severe aortic stenosis and low (< 40 %) left ventricular ejection fraction. Am. J. Cardiol. 2012;109:1031–1037.
  3. Biederman RW, Magovern JA, Grant SB, et al. LV reverse remodeling imparted by aortic valve replacement for severe aortic stenosis; is it dura-ble? A cardiovascular MRI study sponsored by the American Heart Association. J. Cardiothorac. Surg. 2011;6:53.
  4. Broyd CJ, Sen S, Mikhail GW, et al. Myocardial ischemia in aortic stenosis: Insights from arterial pulse-wave dynamics after percutaneous aortic valve replacement. Trends. Cardiovasc. Med. 2013;23:185–191.
  5. Clavel MA, Fuchs C, Burwash IG, et al. Predictors of outcomes in low-flow, low-gradient aortic stenosis: results of the multicenter TOPAS study. Circulation. 2008;118 (Suppl. 1):234–242.
  6. Connolly H, Oh J, Orsulak T, et al. Aortic valve replacement for aortic stenosis with left ventricular dysfunction. Prognostic indicators. Circulation. 1997;95:2395–2400.
  7. Halkos ME, et al. Aortic valve replacement for aortic stenosis in patients with left ventricular dysfunction. Ann. Thorac. Surg. 2009;88:746–751.
  8. Lakoumentas JA, Panou FK, et al. The Tei index of myocardial performance: applications in cardiology. Hellenic. J. Cardiol. 2005;46:52–58.
  9. Lang R, Bierig M, Devereux R, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European association of echocardiography, a Branch of the European Society of Cardiology. J. Am. Soc. Echocardiogr. 2005;18:1440–1145.
  10.  Levy F, Laurent M, Monin JL, et al. Aortic valve replacement for low-flow/low-gradient aortic stenosis. Operative risk stratification and long-term outcome: a European multicenter study. J. Am. Coll. Cardiol. 2008;51:1466–1472.
  11.  Matos J, Kronzon I, Panagopoulos G, Perk G. Mitral annular plane systolic excursion as a surrogate for left ventricular ejection fraction. J. Am. Soc. Echocardiogr. 2012;25(9):969–974.
  12.  Monin JL, Quere JP, Monchi M, et al. Low-gradient aortic stenosis: operative risk stratification and predictors for long-term outcome: a multicenter study using dobutamine stress hemodynamics. Circulation. 2003;108:319 –324.
  13.  Nagueh SF, Appleton CP, Gillebert TC. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography. J. Am. Soc. Echocardiogr. 2009;22:107–133.
  14.  Nishimura RA, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:1–96.
  15.  Otto CM. Valvular aortic stenosis: Disease severity and timing of intervention. J. Am. Coll. Cardiol. 2006;47:2141–2151.
  16.  Pai RG, Varadarajan P, Razzouk A. Survival benefit of aortic valve replacement in patients with severe aortic stenosis with low ejection fraction and low gradient with normal ejection fraction. Ann. Thorac. Surg. 2008;86:1781–1790.
  17.  Pibarot P, Dumesnil J. Low-flow, low-gradient aortic stenosis with normal and depressed
left ventricular ejection fraction. J. Am. Coll. Cardiol. 2012;19:1845–1853.
  18.  Quere JP, Monin JL, Levy F, et al. Influence of preoperative left ventricular contractile reserve on postoperative ejection fraction in low-gradient aortic stenosis. Circulation. 2006;113:1738–1744.
  19.  Quinones M, Otto C, Stoddard M, et al. Recommendations for Quantification of Doppler Echocardiography: A Report From the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J. Am. Soc. Echocardiogr. 2002;15:167–184.
  20.  Ross JJr. Afterload mismatch and preload reserve: A concep- tual framework for the analysis of ventricular function. Progr. Cardiovasc. Dis. 1976;18:255–264.
  21.  Tarantini G, et al. Aortic valve replacement in severe aortic stenosis with left ventricular dysfunction: determinants of cardiac mortality and ventricular function recovery. Eur. J. Cardio-thoracic Surgery. 2003;24:879–885.
  22.  Vaquette B, Corbineau H, Laurent M, et al. Valve replacement in patients with critical aortic stenosis and depressed left ventricular function: predictors of operative risk, left ventricular function recovery, and long-term outcome. Heart. 2005;91:1324–1329.
  23.  Vahanian A, Alfieri O, et al. Guidelines on the management of valvular heart disease (version 2012) The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. J. Cardio-Thoracic Surgery. 2012;42:S12–S18.
  24. Vizzardi Е, D’Aloia A, Rocco E, et al. How should we measure left atrium size and function? J. Clin. Ultrasound. 2012;40:155–166.
  25.  Zoghbi W, Chair J, et al. Recommendations for Evaluation of Prosthetic Valves with Echocardiography and Doppler Ultrasound: A Report From the American Society of Echocardiography’s Guidelines and Standards Committee and the Task Force on Prosthetic Valves, Developed in Conjunction With the American College of Cardiology Cardiovascular Imaging Committee. J. Am. Soc. Echocardiogr. 2009;22:975–1014.

  

[PDF] [Contents]  

  

 

Surgical treatment of left ventricular aneurysm of posterior basal localization

V.I. Ursulenko, О.K. Gogaeva, L.V. Jacob, M.L. Rudenko, N.M. Verich

References

1. Akchurin RS, Shyriaev AA, Haliautdinov DM, et al. Moscow, 2006. 70 р. (in  Rus.).

2. Ursulenko VI. Heart and vessels. 2009;1:86–91(in  Rus.).

3. Codini M.A, Ruggie N.T, Goldin M.D, et al. Diaphragmatic left ventricular aneurysm clinical features, surgical treatment, and longterm follow-up in 22 patients. Arch. Intern. Med. 1982;142 (4):711–714.

4. Jatene A.O. Left ventricular aneurysmectomy resection on reconstruction. J. Thorac. Cardiovasc. Surg. 1985;59:321.

5. Konstantinov I, Mickleborough L.L, Graba J. Intraventricular mitral annuloplasty technique for use with repair of posterior left ventricular aneurysm. From the Divisions of Cardiac Surgery, Cardiology, and Radiology, University BScb, Naeem Merchant, MDc Toronto, Ontario. Canada.

6. Lioulias A.G, Kokotsakis J.N, Skouteli E.A.T, Boulafendis D.G. Postinfarct left ventricular aneursym posterior non)ischemic left ventricular aneurysm. J. Cardiovasc. Surg.: Report of 2 surgical cases. Minerva Medica, Torino, Italie. 1960;43,6:833–836.

7. Mattila S, Jаrvinen A, Merikallio E, et al. Ischaemic cardiac aneurysms and ventricular septal defects: surgical treatment with and without revascularization department of thoracic and cardiovascular surgery, University Central Hospital, Helsinki, Finland. Scand. Cardiovasc. J. 1980;14,3:257–262.

8. Otterstad J.E, Forfang K, Vatne K, Frysaker T. Posterior left ventricular aneurysm due to occlusion of the circumflex coronary artery with recurrent ventricular tachycardia. Case report of Medical Department and Department of Radiology and Surgical Department: Rikshospitalet, Oslo, Norway. DOI: 10.3109/14017438209101812.

.

 

[PDF] [Contents]  

  

 

2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation

References

1. Acosta RD, Abraham NS, Chandrasekhara V, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc. 2016; 83:3–16.
2. Anderson E, Johnke K, Leedahl D, et al. Novel oral anticoagulants vs warfarin for the management of postoperative atrial fibrillation: clinical outcomes and cost analysis. Am J Surg. 2015;210:1095–102.
3. Ansell JE. Universal, class-specific and drugspecific reversal agents for the new oral anticoagulants. J Thromb Thrombolysis. 2016;41:248–52.
4. Austin JH, Stearns CR, Winkler AM, et al. Use of the chromogenic factor X assay in patients transitioning from argatroban to warfarin therapy. Pharmacotherapy. 2012;32:493–501.
5. Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med. 2013;368:2113–24.
6. Bayer Healthcare, Janssen Pharmaceuticals, Inc. Rivaroxaban prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/ 2013/022406s004lbl.pdf. Accessed March 14, 2016.
7. Benzon HT, Avram MJ, Green D, et al. New oral anticoagulants and regional anaesthesia. Br J Anaesth. 2013;111 Suppl 1:i96–113.
8. Beyer-Westendorf J, Gelbricht V, Forster K, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J. 2014;35:1888–96.
9. Birnie DH, Healey JS, Wells GA, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013;368:2084–93.
10. Boehringer Ingelheim Pharmaceuticals, Inc. Dabigatran prescribing information. Available at: http:// www.accessdata.fda.gov/drugsatfda_docs/label/2013/ 022512s017lbl.pdf. Accessed March 14, 2016.
11. Bristol-Myers Squibb Company, Pfizer Inc. Apixaban prescribing information. Available at: http:// www.accessdata.fda.gov/drugsatfda_docs/label/2012/ 202155s000lbl.pdf. Accessed March 14, 2016.
12. Burnett AE, Mahan CE, Vazquez SR, et al. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016;41:206–32.
13. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the Management of Atrial Fibrillation. Eur Heart J. 2012;33:2719–47.
14. Cappato R, Marchlinski FE, Hohnloser SH, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015;36:1805–11.
15. Chang M, Yu Z, Shenker A, et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, andsafety of apixaban. J ClinPharmacol.2016;56:637–45.
16. Chao TF, Liu CJ, Wang KL, et al. Using the CHA2DS2-VASc score for refining stroke risk stratification in ’low-risk’ Asian patients with atrial fibrillation. J Am Coll Cardiol. 2014;64:1658–65.
17. Chao TF, Wang KL, Liu CJ, et al. Age threshold for increased stroke risk among patients with atrial fibrillation: a nationwide cohort study from Taiwan. J Am Coll Cardiol. 2015;66:1339–47.
18. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837–47.
19. Cohen AT, Spiro TE, Buller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368:513–23.
20. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.
21. Daiichi Sankyo Inc. Edoxaban prescribing information. Available at: http://www.accessdata.fda.gov/ drugsatfda_docs/label/2015/206316lbl.pdf. Accessed March 14, 2016.
22. Di Biase L, Burkhardt JD, Santangeli P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation. 2014;129:2638–44.
23. Dias C, Moore KT, Murphy J, et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis. Am J Nephrol. 2016;43:229–36.
24. Douketis J, Weitz JI, Murphy S, et al. Perioperative adverse outcomes in patients with atrial fibrillation taking edoxaban or warfarin: analysis of the ENGAGE AFTIMI 48 Trial (abstr). J Am Coll Cardiol. 2015;65:A2092.
25. Douketis JD, Healey JS, Brueckmann M, et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RELY trial. Thromb Haemost. 2015;113:625–32.
26. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373:823–33.
27. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e326S–50S.
28. Dunn AS, SpyropoulosAC, Turpie AG. Bridgingtherapy in patients on long-term oral anticoagulants who require surgery: theProspectivePeri-operativeEnoxaparinCohort Trial (PROSPECT). J Thromb Haemost. 2007;5:2211–8.
29. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206–14.
30. Eisen GM, Baron TH, Dominitz JA, et al. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastrointest Endosc. 2002;55:775–9.
31. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949–56.
32. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest.2012;141:e278S–325S.
33. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58:395–401.
34. Feng W, Wu K, Liu Z, et al. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis. Thromb Res. 2015;136:1133–44.
35. Flaker GC, Theriot P, Binder LG, et al. Management of periprocedural anticoagulation: a survey of contemporary practice. J Am Coll Cardiol. 2016;68:217–26.
36. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33:1500–10.
37. Friberg L, Skeppholm M, Terent A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol. 2015;65:225–32.
38. Gage BF, van WC, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110:2287–92.
39. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70.
40. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151:713–9.
41. Gallego P, Roldan V, Marin F, et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med. 2014;127:1083–8.
42. Garcia D, Alexander JH, Wallentin L, et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood. 2014;124:3692–8.
43. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.
44. Gogarten W, Vandermeulen E, Van AH, et al. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol. 2010;27:999–1015.
45. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.
46. Grove EL, Hossain R, Storey RF. Platelet function testing and prediction of procedural bleeding risk. Thromb Haemost. 2013;109:817–24.
47. Gullov AL, Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. Arch Intern Med. 1999;159:1322–8.
48. Healey JS, Eikelboom J, Douketis J, et al. Periprocedural bleeding and thromboembolic events with dabigatran comparedwithwarfarin: results fromtheRandomized Evaluation of Long-Term Anticoagulation Therapy (RELY) randomized trial. Circulation. 2012;126:343–8.
49. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27: 949–53.
50. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with nonvalvular atrial fibrillation. Europace. 2013;15:625–51.
51. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467–507.
52. Horlocker TT,WedelDJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med. 2010;35:64–101.
53. Huisman MV, Quinlan DJ, Dahl OE, et al. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes. 2010;3:652–60.
54. Jaffer AK, Ahmed M, Brotman DJ, et al. Lowmolecular- weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. J Thromb Thrombolysis. 2005;20:11–6.
55. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1–76.
56. Kovacs RJ, Flaker GC, Saxonhouse SJ, et al. Practical management of anticoagulation in patients with atrial fibrillation. J Am Coll Cardiol. 2015;65:1340–60.
57. Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2010;70:703–12.
58. Lane DA, Lip GY. Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation. 2012;126:860–5.
59. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776–86.
60. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375:807–15.
61. Liew A, Douketis J. Perioperative management of patients who are receiving a novel oral anticoagulant. Intern Emerg Med. 2013;8:477–84.
62. Lip GY, Nielsen PB, Skjoth F, et al. The value of the European Society of Cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score: a nationwide cohort study. Chest. 2014;146:1337–46.
63. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factorbased approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263–72.
64. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110:1042–6.
65. Malato A, Saccullo G, Lo CL, et al. Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecularweight heparin. J Thromb Haemost. 2010;8:107–13.
66. Malloy PC, Grassi CJ, Kundu S, et al. Consensus guidelines for periproceduralmanagement of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2009;20:S240–9.
67. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736–47.
68. Narouze S, Benzon HT, Provenzano DA, et al. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the NorthAmericanNeuromodulation Society, and theWorld Institute of Pain. Reg Anesth PainMed. 2015;40:182–212.
69. Nin T, Sairaku A, Yoshida Y, et al. A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. Pacing Clin Electrophysiol. 2013;36:172–9.
70. Nutescu EA. Oral anticoagulant therapies: balancing the risks. Am J Health Syst Pharm. 2013;70:S3–11.
71. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.
72. Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost. 2012;107:1172–9.
73. Omran H, Bauersachs R, Rubenacker S, et al. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost. 2012;108:65–73.
74. Parasrampuria DA, Marbury T, Matsushima N, et al. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. Thromb Haemost. 2015;113:719–27.
75. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.
76. Perry DJ, Noakes TJ, Helliwell PS. Guidelines for the management of patients on oral anticoagulants requiring dental surgery. Br Dent J. 2007;203:389–93.
77. Pisters R, Lane DA, Nieuwlaat R, et al. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100.
78. Pollack CV Jr., Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015; 373:511–20.
79. Ridout G, de la Motte S, Niemczk S, et al. Effect of renal function on edoxaban pharmacokinetics (PK) and on population PK/PK-PD model (abstr). J Clin Pharmacol. 2009;49:1124.
80. Saccullo G, Malato A, Raso S, et al. Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: the use of fixed sub-therapeutic doses of lowmolecular weight heparin. Am J Hematol. 2012;87: 388–91.
81. Schulman S, Carrier M, Lee AY, et al. Perioperative management of dabigatran: a prospective cohort study. Circulation. 2015;132:167–73.
82. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119:3016–23.
83. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–4.
84. SherwoodMW,Douketis JD, PatelMR, et al.Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition ComparedWith Vitamin K Antagonism for Prevention of Stroke And Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;129:1850–9.
85. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413–24.
86. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012;120:2954–62.
87. Spyropoulos AC, Turpie AG, Dunn AS, et al. Clinical outcomes with unfractionated heparin or lowmolecular- weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost. 2006;4:1246–52.
88. Steinberg BA, Peterson ED, Kim S, et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation. 2015;131:488–94.
89. Veitch AM, Vanbiervliet G, Gershlick AH, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Gut. 2016;65:374–89.
90. Witt DM, Clark NP, Kaatz S, et al. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016;41:187–205.
91. Wysokinski WE, McBane RD, Daniels PR, et al. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc. 2008;83:639–45.
92. Zaca V, Marcucci R, Parodi G, et al. Management of antithrombotic therapy in patients undergoing electrophysiological device surgery. Europace. 2015;17:840–54.

 

[PDF] [Contents]